Aspirin response: Differences in serum thromboxane B2 levels between clinical studies

Article Article scientifique Article Aspirin response: Differences in serum thromboxane B2 levels between clinical studies eng 2016 author Brun Charlotte 555647 author Daali Youssef 46042 author Combescure Christophe 0000-0003-2631-4780 670542 author Zufferey Bakos Anne 527383 author Michelson Alan D author Fontana Pierre 135328 author Reny Jean-Luc 0000-0002-7528-7363 704339 author Frelinger Andrew L (3rd) 196-202 10.3109/09537104.2015.1072147 26270593 0953-7104 Serum thromboxane B2 (TxB2) is a specific marker of platelet inhibition by aspirin. Yet, TxB2 levels differ by up to 10-fold between some aspirin-treated patient cohorts. This study aimed to identify factors responsible for differences in serum TxB2 between cohorts in the ADRIE study (n = 657) and the BOSTON study (n = 678) of aspirin-treated cardiovascular patients originally tested with different ELISA assays. TxB2 levels were assessed in representative subgroups of the two cohorts (34 samples in BOSTON and 39 in ADRIE) by both ELISAs, as well as liquid chromatography and tandem mass spectroscopy (MS). A multivariate analysis was performed on the whole cohort database to identify determinants of the difference of TxB2 levels between cohorts. There was no systematic bias between the original ELISA TxB2 values and the MS values and the median difference was small, 0.12 ng/ml, thus not explaining the difference between median TxB2 levels in the two study populations (7 and 0.6 ng/ml in the ADRIE and BOSTON studies, respectively). In the combined dataset of the ADRIE and BOSTON cohorts (n = 1342), body mass index, age, gender, aspirin dose, time from aspirin intake to blood draw, NSAID intake, platelet count and C-reactive protein were significantly associated with TxB2 levels. After adjustment for patient characteristics, the difference between cohorts did not decrease. Unexplained differences in serum TxB2 levels in different populations of aspirin-treated cardiovascular patients suggest that further studies are needed to confirm the role of serum TxB2 level as a prognostic factor or rather as a marker of therapeutic observance. Dewey 613 Dewey 615 Dewey 616 Dewey 618.97 31 Section des sciences pharmaceutiques 17 56 Département de médecine 221 64 Département de santé et médecine communautaires 22A 65 Département de réadaptation et gériatrie 22B false 88 Epidémiologie clinique 115 11 Plaquettes et antithrombotiques 13 302 Groupe Desmeules Jules (pharmacologie/toxicologie) 567 1280 Pharmaco-omiques et médecine de précision 1003 Platelets 27 3 2e9af0f9-2962-4bbf-8647-a37b27796ea2 Article (Published version) Restricted serum TxB2 final.pdf 302624 application/pdf restrictedAccess Faculté des sciences / Section des sciences pharmaceutiques Faculté de médecine / Section de médecine clinique / Département de médecine Faculté de médecine / Section de médecine clinique / Département de santé et médecine communautaires Faculté de médecine / Section de médecine clinique / Département de réadaptation et gériatrie

Title	Published in	Year	Views	Downloads

Réponse à l'aspirine : différence de taux de thromboxane B2 sérique entre deux études cliniques		2016	853	312
Aspirin response: Differences in serum thromboxane B2 levels between clinical studies	Platelets	2016	716	1

Archive ouverte UNIGE

Brun, Charlotte